184 related articles for article (PubMed ID: 17920266)
21. Solubilized phenyl-pyrazole ureas as potent, selective 5-HT(2A) inverse-agonists and their application as antiplatelet agents.
Dosa PI; Strah-Pleynet S; Jayakumar H; Casper M; Decaire M; Xiong Y; Lehmann J; Choi K; Elwell K; Wong A; Webb RR; Adams JW; Ramirez J; Richman JG; Thomsen W; Semple G; Teegarden BR
Bioorg Med Chem Lett; 2009 Sep; 19(18):5486-9. PubMed ID: 19665894
[TBL] [Abstract][Full Text] [Related]
22. Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.
Cheng XC; Liu XY; Xu WF; Guo XL; Zhang N; Song YN
Bioorg Med Chem; 2009 Apr; 17(8):3018-24. PubMed ID: 19329327
[TBL] [Abstract][Full Text] [Related]
23. Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS.
Burns CJ; Harte MF; Bu X; Fantino E; Giarrusso M; Joffe M; Kurek M; Legge FS; Razzino P; Su S; Treutlein H; Wan SS; Zeng J; Wilks AF
Bioorg Med Chem Lett; 2009 Feb; 19(4):1206-9. PubMed ID: 19128971
[TBL] [Abstract][Full Text] [Related]
24. Polycyclic N-heterocyclic compounds. Part 62: Reaction of N-(quinazolin-4-yl)amidine derivatives with hydroxylamine hydrochloride and anti-platelet aggregation activity of the products.
Okuda K; Zhang YX; Ohtomo H; Hirota T; Sasaki K
Chem Pharm Bull (Tokyo); 2010 Mar; 58(3):369-74. PubMed ID: 20190443
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of 2,3-disubstituted 1,4-naphthoquinones as antiplatelet agents.
Lien JC; Wu CR; Hour MJ; Huang LJ; Huang TF; Kuo SC
Arch Pharm (Weinheim); 2008 Oct; 341(10):639-44. PubMed ID: 18720342
[TBL] [Abstract][Full Text] [Related]
26. Pyridazines part 41: synthesis, antiplatelet activity and SAR of 2,4,6-substituted 5-(3-oxo-3-phenylprop-1-en-1-yl)- or 5-(3-phenylprop-2-enoyl)pyridazin-3(2H)-ones.
Crespo A; Meyers C; Coelho A; Yáñez M; Fraiz N; Sotelo E; Maes BU; Laguna R; Cano E; Lemière GL; Raviña E
Bioorg Med Chem Lett; 2006 Feb; 16(4):1080-3. PubMed ID: 16290144
[TBL] [Abstract][Full Text] [Related]
27. Nonprostanoid prostacyclin mimetics. 3. Structural variations of the diphenyl heterocycle moiety.
Meanwell NA; Rosenfeld MJ; Trehan AK; Romine JL; Wright JJ; Brassard CL; Buchanan JO; Federici ME; Fleming JS; Gamberdella M
J Med Chem; 1992 Sep; 35(19):3498-512. PubMed ID: 1404231
[TBL] [Abstract][Full Text] [Related]
28. Derivatives of 7-amino-1,2,3,4-tetrahydroisoquinoline and isophthalic acids as novel fibrinogen receptor antagonists.
Malovichko OL; Petrus AS; Krysko AA; Kabanova TA; Andronati SA; Karaseva TL; Kiriyak AV
Bioorg Med Chem Lett; 2006 Oct; 16(20):5294-7. PubMed ID: 16919941
[TBL] [Abstract][Full Text] [Related]
29. Discovery of diphenylcarbamate derivatives as highly potent and selective IP receptor agonists: orally active prostacyclin mimetics. Part 3.
Hattori K; Tanaka A; Okitsu O; Tabuchi S; Taniguchi K; Nishio M; Koyama S; Higaki M; Seki J; Sakane K
Bioorg Med Chem Lett; 2005 Jun; 15(12):3091-5. PubMed ID: 15914004
[TBL] [Abstract][Full Text] [Related]
30. Discovery of novel acetanilide derivatives as potent and selective beta3-adrenergic receptor agonists.
Maruyama T; Onda K; Hayakawa M; Matsui T; Takasu T; Ohta M
Eur J Med Chem; 2009 Jun; 44(6):2533-43. PubMed ID: 19232786
[TBL] [Abstract][Full Text] [Related]
31. Analysis of anti-PDE3 activity of 2-morpholinochromone derivatives reveals multiple mechanisms of anti-platelet activity.
Abbott BM; Thompson PE
Bioorg Med Chem Lett; 2006 Feb; 16(4):969-73. PubMed ID: 16290931
[TBL] [Abstract][Full Text] [Related]
32. Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
Colotta V; Lenzi O; Catarzi D; Varano F; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Traini C; Pedata F; Morizzo E; Moro S
J Med Chem; 2009 Apr; 52(8):2407-19. PubMed ID: 19301821
[TBL] [Abstract][Full Text] [Related]
33. Discovery and synthesis of a novel series of quinoline-based thrombin receptor (PAR-1) antagonists.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee WJ; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Bryant M; Lau J
Bioorg Med Chem Lett; 2006 Mar; 16(6):1544-8. PubMed ID: 16380251
[TBL] [Abstract][Full Text] [Related]
34. Metabolism-based identification of a potent thrombin receptor antagonist.
Clasby MC; Chackalamannil S; Czarniecki M; Doller D; Eagen K; Greenlee W; Kao G; Lin Y; Tsai H; Xia Y; Ahn HS; Agans-Fantuzzi J; Boykow G; Chintala M; Foster C; Smith-Torhan A; Alton K; Bryant M; Hsieh Y; Lau J; Palamanda J
J Med Chem; 2007 Jan; 50(1):129-38. PubMed ID: 17201416
[TBL] [Abstract][Full Text] [Related]
35. Discovery and evaluation of potent P1 aryl heterocycle-based thrombin inhibitors.
Young MB; Barrow JC; Glass KL; Lundell GF; Newton CL; Pellicore JM; Rittle KE; Selnick HG; Stauffer KJ; Vacca JP; Williams PD; Bohn D; Clayton FC; Cook JJ; Krueger JA; Kuo LC; Lewis SD; Lucas BJ; McMasters DR; Miller-Stein C; Pietrak BL; Wallace AA; White RB; Wong B; Yan Y; Nantermet PG
J Med Chem; 2004 Jun; 47(12):2995-3008. PubMed ID: 15163182
[TBL] [Abstract][Full Text] [Related]
36. Cyclic urea derivatives as potent NK1 selective antagonists.
Shue HJ; Chen X; Shih NY; Blythin DJ; Paliwal S; Lin L; Gu D; Schwerdt JH; Shah S; Reichard GA; Piwinski JJ; Duffy RA; Lachowicz JE; Coffin VL; Liu F; Nomeir AA; Morgan CA; Varty GB
Bioorg Med Chem Lett; 2005 Sep; 15(17):3896-9. PubMed ID: 16019209
[TBL] [Abstract][Full Text] [Related]
37. Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation.
de Candia M; Liantonio F; Carotti A; De Cristofaro R; Altomare C
J Med Chem; 2009 Feb; 52(4):1018-28. PubMed ID: 19193009
[TBL] [Abstract][Full Text] [Related]
38. Heteroatom-linked indanylpyrazines are corticotropin releasing factor type-1 receptor antagonists.
Corbett JW; Rauckhorst MR; Qian F; Hoffman RL; Knauer CS; Fitzgerald LW
Bioorg Med Chem Lett; 2007 Nov; 17(22):6250-6. PubMed ID: 17888659
[TBL] [Abstract][Full Text] [Related]
39. A new insight of anti-platelet effects of sirtinol in platelets aggregation via cyclic AMP phosphodiesterase.
Liu FC; Liao CH; Chang YW; Liou JT; Day YJ
Biochem Pharmacol; 2009 Apr; 77(8):1364-73. PubMed ID: 19426675
[TBL] [Abstract][Full Text] [Related]
40. New trisubstituted 1,2,4-triazole derivatives as potent ghrelin receptor antagonists. 3. Synthesis and pharmacological in vitro and in vivo evaluations.
Moulin A; Demange L; Ryan J; Mousseaux D; Sanchez P; Bergé G; Gagne D; Perrissoud D; Locatelli V; Torsello A; Galleyrand JC; Fehrentz JA; Martinez J
J Med Chem; 2008 Feb; 51(3):689-93. PubMed ID: 18193826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
